Q-omics provides the consensus-scored CAPN11 profile across patient tissues and cancer cell-line models. CAPN11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CAPN11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CAPN11 protein abundance shows 20,373 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where CAPN11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN11 survival associations across molecular data types. CAPN11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN11 RNA expression–survival associations across cancer types. High CAPN11 expression shows unfavorable associations in UVM, STAD, MESO and OV, but favorable associations in HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CAPN11 RNA expression.
This table summarizes CAPN11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN11 shows lower tumor expression in LUAD and BRCA and higher tumor expression in KIRC, THCA, HNSC and LIHC. The KIRC box plot shows higher CAPN11 RNA expression in tumor versus normal tissue (log2 FC = +0.946, t-test p < 0.001).
This table shows molecular features associated with CAPN11 in patient tissues and cancer cell lines. In patient samples, CAPN11 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
